CME Spotlight - Beyond Corticosteroids: Novel Therapeutics for Refractory ITP and wAIHA

CME Spotlight banner image.

Target Audience

Healthcare Professionals

Learning Objectives

1. Describe the pathogenesis of immune-mediated cytopenias, including immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to enhance the identification and understanding of these conditions.
2. Understand and implement current corticosteroid-sparing approaches to improve efficacy, patient safety, and quality of life.
3. Apply clinical data and mechanisms of action of new and emerging therapies to tailor treatment strategies in autoimmune cytopenias.
4. Increase clinician confidence in integrating new and emerging therapies into practice.

Activity Disclosures

This educational activity is supported by an independent medical educational grant from Sanofi.

This Wiley developed grant-funded resource provides ASH Clinical News readers with convenient access to information that may be of interest. It should not be considered an ASH endorsement or recommendation of the grantor’s products, services, policies, or procedures. ASH Clinical News editors were not involved in the development of this content.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
Course opens: 
02/12/2026
Course expires: 
02/11/2029
Cost:
$0.00
David J. Kuter MD, DPhil

David J. Kuter MD, DPhil

Director of Clinical Hematology, Massachusetts General Hospital Cancer Center; Professor of Medicine, Harvard Medical School, Boston, MA

David J. Kuter MD, DPhil discloses the following: Research: Fulcrum, Novartis, Principia, Sanofi, Takeda

Consulting: Alexion, Alpine, Amgen, argenx, BioCryst, Blackstone, Bristol Myers Squibb, Cardurion, Caremark, Chugai, Cyrus, Hengrui, Hutchmed, Iconic Bio, Immunovant, Inmagenebio, Kaigen, Kyowa-Kirin, Lilly, Medscape, Merck Sharp Dohme, New York Blood Center, Nexcella, Novartis, Nurix, Nuvig, Ouro, Peerview, PER, Pfizer, Platelet Disorder Support Association, Principia, Regeneron, Rigel, Sanofi, Seismic, Sobi, Takeda, Timberlyne, UCB, Up-To-Date, Vertex, Verve.

Sandhya R. Panch, MD, MPH

Sandhya R. Panch, MD, MPH

Medical Director of Transfusion, Fred Hutchinson Cancer Center; Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA

Sandhya R. Panch, MD, MPH discloses the following: Consulting: Johnson and Johnson, Recordati Rare Diseases Inc., Sanofi

John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this enduring CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™

Price

Cost:
$0.00
Please login or register to take this course.